CX1106 / Konruns Pharma - LARVOL DELTA

HNSCC: Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.; N=30 ➔ 0; Trial completion date: Dec 2022 ➔ Mar 2020; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Dec 2021 ➔ Mar 2020

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck